Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

BACKGROUND: Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted. METHODS: We used data from dossiers prepared for the German Federal Joint Committee based on two phase III randomized trials of carfilzomib-based thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Katja, Ludwig, Heinz, Rieth, Achim, Lebioda, Andrea, Goldschmidt, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962286/
https://www.ncbi.nlm.nih.gov/pubmed/31552577
http://dx.doi.org/10.1007/s11136-019-02307-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962286/
https://www.ncbi.nlm.nih.gov/pubmed/31552577
http://dx.doi.org/10.1007/s11136-019-02307-5

Ejemplares similares